Time (CENTRAL)

Location

Type

Abstract No.

Poster Board No.

Title

Presenter

1:30-1:45 p.m.

S100a

Education Session

Molecular Targeted Therapy for Differentiated and Anaplastic Thyroid Carcinomas

Christine Chung, MD

1:36-1:48 p.m.

S100bc

Oral Abstract Discussion

Much Ado About ALL CAR T

Rawan Faramand, MD

Time (CENTRAL)

Location

Type

Abstract No.

Poster Board No.

Title

Presenter

8 - 11 a.m.

Hall A

Poster

4587

59

CDH1-mutated clinically advanced urothelial bladder cancer (UBC): A genomic landscape and real-world clinical outcome study (RWCOS).

Kyle Rose, MD

8 - 11 a.m.

Hall A

Poster

3126

324

Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines.

Timothy Shaw, PhD

8 - 11 a.m.

Hall A

Poster

4132

453

ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis.

Jonathan Strosberg, MD

8 - 11 a.m.

Hall A

Poster

2569

411

A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).

Andreas Saltos, MD

8 - 11 a.m.

Hall A

Poster

2598

440

Phase 1B study of avelumab and whole brain radiotherapy (WBRT) in patients with leptomeningeal disease (LMD) from epithelial carcinomas: Final results and molecular analyses with single cell RNA sequencing.

Yolanda Pina, MD

8 - 11 a.m.

Hall A

Poster

2617

459

 Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.

Xuefeng Wang, PhD

8:15-8:30 a.m.

Hall D2

Education Session

Tailoring Post-Neoadjuvant Therapy in TNBC

Hyo Han, MD

1:15-4:15 p.m.

Hall A

Poster

11527

461

PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children’s Oncology Group Pediatric Early-Phase Clinical Trial Network study.

Damon Reed, MD

1:15-4:15 p.m.

Hall A

Poster

9521

284

Real-world treatment patterns and clinical outcomes among subgroups of BRAF-positive metastatic melanoma patients treated with dabrafenib + trametinib.

Zeynep Eroglu, MD

1:15-4:15 p.m.

Hall A

Poster

9534

297

Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Andrew Scott Brohl, MD

1:15-4:15 p.m.

Hall A

Poster

9565

328

Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum: Outcomes for patients with melanoma.

Lilit Karapetyan, MD, MSc

1:15-4:15 p.m.

Hall A

Poster

9574

337

Intralesional therapy, limb infusion/perfusion, and immune checkpoint inhibitors as first-line therapy in surgically unresectable melanoma in-transit metastases.

Danielle K DePalo, MD

1:15-4:15 p.m.

Hall A

Poster

TPS9603

360b

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.

Zeynep Eroglu, MD

3-4:30 p.m.

S100bc

Poster Discussion Session

2517

Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).

Fred Locke, MD

4:24-4:36 p.m.

Hall B1

Oral

Small Cell, Mighty Hopes

Alberto Chiappori, MD

4:30-6 p.m.

Hall D2

Clinical Science Symposium (Panel Moderator, Not Presenting)

Molecular Basis for Young-Onset Colorectal Cancer

Christine Walko

Time (CENTRAL)

Location

Type

Abstract No.

Poster Board No.

Title

Presenter

8 - 11 a.m.

Hall A

Poster

TPS1113

333a

Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC).

Hyo Han, MD

8 - 11 a.m.

Hall A

Poster

8541

168

The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I–III resected NSCLC without known EGFR mutations.

Jhanelle Gray, MD

8 - 11 a.m.

Hall A

Poster

9075

63

Circulating tumor DNA (ctDNA) monitoring to inform maintenance outcomes in patients (pts) with advanced NSCLC treated with induction atezolizumab+carboplatin+nab-paclitaxel (A+CnP).

Bruna Pellini, MD

8 - 11 a.m.

Hall A

Poster

9125

113

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.

Andreas Saltos, MD

8 - 11 a.m.

Hall A

Poster

532

362

A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer.

Hyo Han, MD

8 - 11 a.m.

Hall A

Poster

541

371

Impact of endocrine therapy adherence on racial disparities in breast cancer survival.

Kimberley Lee, MD

8 - 11 a.m.

Hall A

Poster

596

426

Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial.

Hyo Han, MD

8 - 11 a.m.

Hall A

Poster

598

428

Association between genomic alterations and response of triple-negative breast cancers (TNBC) to talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy (NACT).

Hatem Soliman, MD

8 - 11 a.m.

Hall A

Poster

TPS629

452a

Phase 1 dose-escalation, dose-expansion trial of intratumoral HER2- and HER3-primed dendritic cells injections for the treatment of early-stage TNBC and HR low positive breast cancer: DecipHER trial.

Ricardo Costa, MD

Time (CENTRAL)

Location

Type

Abstract No.

Poster Board No.

Title

Presenter

8-9 a.m.

S100bc

Case-based Panel (Panel Moderator, not presenting)

Multidisciplinary Management Challenges in Merkel Cell Carcinoma

Zeynep Eroglu, MD

8 - 11 a.m.

Hall A

Poster

TPS7585

132b

KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.

Hayder Saeed, MD

8 - 11 a.m.

Hall A

Poster

7023

153

Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.

Bijal Shah, MD

9:45-10 a.m.

S404

Education Session

Fencing in Our Lawns: Where Do We Stand on Boundaries in Medicine?

Monica Sheila Chatwal, MD

11:30 a.m. -1 p.m.

E450

Poster Discussion Session

7020

Refining risk stratification in CMML: A comprehensive assessment of the IPSS-M and other molecularly informed models.

Luis Aguirre, MD

1:15-1:30 p.m.

S100bc

Education Session

A Brain: Neurotoxicity of Immunotherapy

Peter Forsyth, MD

1:15-4:15 p.m.

Hall A

Poster

6021

13

Association of neutrophil-lymphocyte ratio (NLR) with clinical outcomes in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with combination of cetuximab and nivolumab (C+N).

Robin Park

1:15-4:15 p.m.

Hall A

Poster

6051

43

Safety and efficacy of time restricted eating (TRE) in improving response to immunotherapy in head and neck cancer (HNSCC) patients.

Humaira Sarfraz, MD

1:15-4:15 p.m.

Hall A

Poster

6053

45

Evaluation of tumor mutation burden (TMB) in tumor (tDNA) and plasma cell free DNA (cfDNA) in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with a combination of cetuximab and nivolumab (C+N).

Christine Chung, MD

1:15-4:15 p.m.

Hall A

Poster

1567

161

Toxicity reporting consistency and subjective minimizing language use in colorectal cancer (CRC) and pancreatic cancer (PaC) clinical trials: A systematic review of phase III randomized controlled trials (RCTs) presented at ASCO between 2012-2022.

James Yu, MD

1:15-4:15 p.m.

Hall A

Poster

12052

420

Association of frailty and high-risk immuno-nutritional score with outcomes in patients with relapsed and refractory multiple myeloma treated with chimeric antigen receptor T-cells.

Karnav Modi, MBBS

2:21-2:33 p.m.

E450

Poster Discussion Session

Moving Beyond R-CHOP and Excessive Imaging in Non-Hodgkin Lymphoma

Julio Chavez, MD

3-4 p.m.

Hall D2

Case-based Panel (Panel Moderator, not presenting)

ctDNA in the Management of Early Colorectal Cancer: The Time Has Come!

Richard D Kim, MD

3-4:30 p.m.

E450

Poster Discussion Session

8012

Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).

Doris K. Hansen, MD

3:24-3:36 p.m.

Hall D1

Oral

9511

Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).

Zeynep Eroglu, MD

3:30-3:45 p.m.

S504

Education Session

Emerging Strategies in Osteosarcoma and Ewing Sarcoma

Damon Reed, MD

4:30-6 p.m.

S504

Poster Discussion Session (Panel Moderator, Not Presenting)

Pediatric Oncology

Damon Reed, MD

4:30-6 p.m.

E451

Poster Discussion Session

6013

A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.

Christine Chung, MD

4:30-6 p.m.

S102

Poster Discussion Session

1517

AI-based radiomic biomarkers to predict PD-(L)1 immune checkpoint inhibitor response within PD-L1 high/low/negative expression categories in stage IV NSCLC.

George R. Simon, MD, FCCP, FACP